Results 61 to 70 of about 33,791,512 (292)

Glucagon-like peptide-1 agonist use for obesity treatment in patients with left ventricular assist devices

JHLT Open
Glucagon-like peptide-1 agonists are effective weight loss treatments, yet few data are available regarding their use in patients with durable left ventricular assist devices.
Michele Edwards, MSN, APRN, Melanie Thomas, MSN, APRN, Maryjane Farr, MD, MSc, Densey Varghese, MSN, APRN, Lauren K. Truby, MD, MS, Jennifer T. Thibodeau, MD, MSCS, Mark H. Drazner, MD, MSc, Matthias Peltz, MD, Justin L. Grodin, MD, MPH, Nicholas S. Hendren, MD   +9 more
doaj   +1 more source

Perioperative Practice Patterns of Anaesthesiologists Surrounding Glucagon-Like Peptide-1 (GLP-1) Agonist Medications [PDF]

Objective: Aspiration of gastric contents during induction of anaesthesia is a rare but well-recognized complication with high morbidity and mortality risk.
Sabrina H. Han, Kyle Ockerman, Heather J. Furnas, Frederik Heath, Meghan Brennan, Sarah C. Sorice-Virk, Patricia Mars, Sonia D. Mehta, Audrey Klenke   +8 more
core   +1 more source

Sonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut‐Liver Axis

Advanced Science, EarlyView.
Researchers developed an engineered probiotic encapsulated in an inulin hydrogel, enabling ultrasound‐triggered intestinal delivery of IL‐22. In MASH model mice, this system remodeled gut microbiota, strengthened the intestinal barrier and reduced portal LPS and hepatic IL‐6.
Chunya Ji, Yan Fang, Shen Zhang, Weichen Xu, Wenyun Guo, Jing Chen, Mingrui Zhu, Congjian Wen, Siming Chen, Yuli Zhu, Huixiong Xu, Haohao Yin   +11 more
wiley   +1 more source

Is ghrelin a glucagon‐like peptide‐1 secretagogue?

Journal of Diabetes Investigation, 2015
Ghrelin was reported to enhance GLP-1 secretion after glucose load in mice.
Ueno, Hiroaki, Nakazato, Masamitsu
openaire   +2 more sources

Intra-islet glucagon-like peptide 1 [PDF]

Journal of Diabetes and its Complications, 2016
Glucagon-like peptide-1 (GLP-1) is originally identified in the gut as an incretin hormone, and it is potent in stimulating insulin secretion in the pancreas. However, increasing evidence suggests that GLP-1 is also produced locally within pancreatic islets.
Genevieve E. Fava, Emily W. Dong, Hongju Wu   +2 more
openaire   +2 more sources

Commentary on “Electroacupuncture Inhibited Spinal Glial Activation in Neuropathic Pain via Glucagon-like Peptide 1/Glucagon-like Peptide 1 Receptor Signaling”

Neurological Sciences and Neurophysiology
Neuropathic pain represents a significant clinical challenge due to its complex etiology and limited treatment options. Traditional pharmacological approaches, particularly opioid therapy, are associated with significant side effects and risk of abuse ...
Hulya Karatas
doaj   +1 more source

Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics

Nature Communications, 2020
Glucagon-like peptide-1 receptor is an important regulator of appetite and glucose homeostasis. Here the authors describe super-resolution microscopy and in vivo imaging compatible fluorescent probes, which reveal endogenous glucagon-like peptide-1 ...
Julia Ast, Anastasia Arvaniti, Nicholas H. F. Fine, Daniela Nasteska, Fiona B. Ashford, Zania Stamataki, Zsombor Koszegi, Andrea Bacon, Ben J. Jones, Maria A. Lucey, Shugo Sasaki, Daniel I. Brierley, Benoit Hastoy, Alejandra Tomas, Giuseppe D’Agostino, Frank Reimann, Francis C. Lynn, Christopher A. Reissaus, Amelia K. Linnemann, Elisa D’Este, Davide Calebiro, Stefan Trapp, Kai Johnsson, Tom Podewin, Johannes Broichhagen, David J. Hodson   +25 more
doaj   +1 more source

Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists? [PDF]

, 2015
Several new medicines are in development for the treatment of type 2 diabetes, and cardiovascular outcome trials are the gold standard for these medicines.
Doggrell, Sheila
core   +1 more source

A Postbiotic‐Inducing Ganoderma applanatum Polysaccharide Repairs the Intestinal Barrier via a Phocaeicola vulgatus ‐ Tridecylic Acid Axis

Advanced Science, EarlyView.
This study identifies GAP2, a bioactive polysaccharide fraction derived from Ganoderma applanatum, as a postbiotic inducer that repairs intestinal barrier damage in a gut microbiota‐dependent manner. GAP2 enriches Phocaeicola vulgatus, which degrades GAP2 and promotes tridecylic acid production, triggering Rho/CDC42 signaling and tight‐junction ...
Chuan Zhang, Miaoyu Li, Tiantian Li, Xiaojie Zang, Haiyang Shi, Yaru Liu, Chengcheng Zhang, Jianxin Zhao, Qixiao Zhai, Wei Chen, Fengwei Tian   +10 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source